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Abstract
Background: End-stage liver disease is currently a major concern among HIV-positive individuals due to
co-infection with hepatotropic virus. Hepatitis C has been pointed out as a remarkable factor for that.
More recently, hepatitis B virus (HBV) infection has also been found to play a role on liver disease in this
population. HIV-HBV co-infection prevalence remains largely unknown in vast areas of Brazil. The
objective of the present study was to estimate the prevalence of HBV and HDV infection in HIV-infected
subjects living in the state of Mato Grosso, in the Central region of Brazil, and compare it to other Brazilian
studies. We also assess epidemiologic data regarding risk factors and vaccinal status.
Methods: HIV-positive individuals followed at the Central Laboratory of the Department of Public Health
of Mato Grosso in the city of Cuiabá composed the sample. Participants answered a specific questionnaire
and had a blood sample taken and tested for serologic markers.
Results: A thousand individuals were interviewed and tested for HBsAg, anti-HBc, anti-HBs and anti-HDV
if positive for HBsAg. Measurements of CD4 and viral load for HIV-1 were also performed. Overall
prevalence of HBV exposure (anti-HBc +ve) was 40.0%, and 3.7% for HBsAg. This prevalence data was
similar or slightly lower than for other Brazilian regions, which ranged from 40% and 3% to 71% and 24%,
respectively. Testing for anti-HDV in the 37 HBsAg positive patients was positive in only one subject.
Factors that showed independent association with HBV exposure, after adjustment, were: male gender,
older age groups, tattooing, and reporting more than ten sexual partners throughout life (p < 0.01). Eighty-
one (27.5%) out of 291 HBV-unexposed individuals who reported vaccination were anti-HBs positive.
Anti-HBs prevalence was higher among those who had higher levels of CD4 by multivariate analysis.
Conclusion: Our data showed HBV infection prevalence similar or slightly lower than that reported in
other regions of Brazil. In addition, our data revealed a less important role for drug injection in the spread
of HIV and HBV in Mato Grosso compared to other regions of the country. The high rate of non-
vaccinated subjects among this HBV-unexposed, HIV-infected population is a matter of considerable health
concern in this region. The relationship between CD4 levels and HBV vaccine response found in the
present study reinforces the need of keeping health care workers alert to this issue.
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Background
Hepatitis B Virus (HBV) infection and its associated com-
plications (cirrhosis and hepatocellular carcinoma) are
the leading cause of chronic liver disease worldwide. An
estimated one third of the global population has been
infected with the virus and more than 350 million people
are chronic carriers [1].
Prevalence of HBV infection is heterogeneous, reaching a
high carrier rate in certain countries and among some sub-
populations. Brazil is a country with intermediate preva-
lence, having high and low prevalence in distinct
geographical areas [2].
Among HIV-infected individuals, HBV infection preva-
lence is approximately ten times higher than in the gen-
eral population, due to shared routes of transmission [3].
Although uncommon until recently, due to the low life
expectancy of HIV-infected persons, clinical manifesta-
tions of chronic hepatitis B in the HAART era are becom-
ing more frequent following the increased survival of
these patients [4].
Chronic HBV infection appears to have its natural pro-
gression modified by HIV coinfection, with significantly
increased mortality attributable to liver disease in co-
infected patients, compared with those with HBV alone
[5]. Decreased clearance rates of HBsAg and HBeAg, reac-
tivation of HBV, higher levels of HBV-DNA, and lower
ALT levels are some of the most important findings that
differentiate HIV-HBV co-infected individuals from those
infected only with HBV [6-8]. Consequently, it is of piv-
otal importance to determine the prevalence of HIV-HBV
co-infection in order to estimate chronic liver disease bur-
den due to HBV among HIV-infected patients.
In Brazil, data on HBV infection among HIV-positive sub-
jects is still scarce. However, some studies, conducted
mainly in the South and Southeast regions (the most
developed and populous parts of the country), have
reported prevalence of HIV-HBV co-infection ranging
from 5.3 to 24.3% [9-13].
There is a lack of information on this issue in Central Bra-
zil, a vast region located in the innermost part of South
America. Furthermore, data on hepatitis D virus infection
in HIV-HBV co-infected patients of this region is also not
available.
The goal of the present study was to estimate the preva-
lence of HBV and HDV infection in HIV-infected patients
living in the state of Mato Grosso – Central Brazil – treated
at the STD/AIDS Reference Unit in the city of Cuiabá,
comparing it with available data from other Brazilian
regions. Epidemiological data regarding risk factors and
vaccinal status was also assessed.
Methods
A cross-sectional study was designed with the goal of
assessing epidemiological and serologic data. In the state
of Mato Grosso, virologic and immunologic assessment
and medical assistance of HIV-infected subjects are pro-
vided by the Department of Public Health at the Central
Laboratory and STD/AIDS Reference Unit, respectively.
Consequently, almost all known HIV-infected persons of
Mato Grosso are referred to this unit to perform viral load
and CD4 measurements, including most of the subjects
treated at private clinics, at which time they were invited
to participate in the study. The survey was conducted over
a six-month period, in view of the recommendation that
these exams be performed every 4 to 6 months.
Individuals were considered eligible if they were over 17
years of age and agreed to answer a specific questionnaire
and have a blood sample taken and tested for serologic
markers.
A standard questionnaire was applied to obtain informa-
tion on demographics, risk factors for HIV and HBV infec-
tion, previous sexually transmitted diseases, and vaccinal
status for HBV.
Blood samples were tested by enzyme immunoassay for
HBV surface antigen, HBsAg (EIE-HBsAg® – Bio-Manguin-
hos, Rio de Janeiro, Brazil), for antibodies against core
antigen (anti-HBc), against HBsAg (anti-HBs) and against
HDV (anti-HDV) – (Hepanostika® Microelisa system anti-
HBc Uni-Form, anti-HBs, and HDV respectively – Biomer-
ieux, Boxtel, The Netherlands).
T-lymphocyte subsets were determined by flow cytometry
technique (Beckton-Dickinson, NJ, USA). HIV1-RNA
detection and measurement were performed by NASBA
(Biomèrieux, Boxtel, The Netherlands).
The Ethics Research Board at the Mato Grosso Federal
University approved the protocol used in the present
study. All surveyed individuals who agreed to participate
were asked to sign informed consent form. Serologic
marker results were used to assistant physicians in order to
provide adequate measures when indicated.
The statistical analysis was based on overall chi-square test
with Yates' correction and Fisher's exact test. When appro-
priate, crude odds ratio and the confidence interval were
calculated to determine the strength of association. Multi-
ple logistic regression models were constructed by SPSS
12.0 software to assess the independent effect of variables.BMC Infectious Diseases 2006, 6:34 http://www.biomedcentral.com/1471-2334/6/34
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In order to compare our results with available data from
other Brazilian regions, we performed a search in the
Medline (National Library of Medicine, US) and LILACS
(Latin America and Caribbean Health Sciences Informa-
tion System, PAHO) electronic databases. Our search
strategy was to combine the terms "brazil," "hiv," "hepati-
tis," and "prevalence" in several ways.
Results
Between January 2004 and June 2004, 1,025 individuals
were approached. Eight refused to participate and 17 were
excluded from analysis due to missing data at the inter-
view or technical difficulties in performing a blood test
(insufficient or inappropriate blood sample). A thousand
individuals were interviewed and tested, corresponding to
Table 1: Demographic and epidemiological characteristics of HIV-positive individuals in the state of Mato Grosso, Central Brazil.
Characteristic N (%) Male N (%) Female N (%) P
Total 1000 (100.0) 530 (53.0) 470 (47.0)
Age group (in yrs.)
17–30 268 (26.8) 100 (18.8) 168 (35.7) 0.000
31–40 408 (40.8) 213 (40.2) 195 (41.5) 0.5
41–50 230 (23.0) 151 (28.5) 79 (16.8) 0.000
51–77 94 (9.4) 66 (12.4) 28 (5.9) 0.6
Supposed route of HIV infection
Unprotected sex 577 (58.8) 403 (76.0) 174 (37.0) 0.000
HIV+ve partner 322 (32.8) 66 (13.2) 256 (54.4) 0.000
Blood transfusion 56 (5.7) 30 (5.6) 26 (5.5) NS
IV-drugs 24 (2.4) 21 (4.0) 3 (0.6) 0.001
Number of sexual partners
1–5 379 (38.1) 98 (18.4) 281 (59.7)
6–10 164 (16.5) 86 (16.2) 78 (16.6)
> 10 451(45.3) 341 (64.3) 110 (23.4) 0.000*
STD
Yes 339 (34.2) 266 (50.7) 73 (15.6) 0.000
No 653 (65.8) 259 (49.3) 394 (84.4)
Tattooing
Yes 134 (13.5) 86 (16.4) 48 (10.3) <0.01
No 857 (86.5) 438 (83.6) 419 (89.7)
Vaccination against hepatitis
Yes 464 (47.6) 239 (46.7) 225 (48.6) 0.6
No 511 (52.4) 273 (53.3) 238 (51.4)
Antiretroviral treatment
Yes 716 (72.0) 402 (76.3) 314 (67.1) <0.05
No 279 (28.0) 125 (23.7) 154 (32.9)
CD4 level (cells/mm3)
0–200 255 (25.5) 143 (27.0) 112 (23.8)
201–350 288 (28.8) 141 (26.6) 147 (31.3)
> 351 457 (45.7) 246 (46.4) 211 (44.9) 0.7*
Viral Load (copies/mm3)
< 80 386 (38.6) 224 (42.2) 162 (34.5)
81–10,000 242 (24.2) 114 (21.5) 128 (27.2)
10,001–100,000 234 (23.4) 115 (21.7) 119 (25.3)
> 100,000 138 (13.8) 77 (14.6) 61 (13.0) 0.2*
* Chi-square for linear trendBMC Infectious Diseases 2006, 6:34 http://www.biomedcentral.com/1471-2334/6/34
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approximately 80% of the population in regular follow-
up with CD4/CD8 and viral load measurements at Cen-
tral Laboratory. Patients originated mainly from Cuiabá
and surrounding counties (71.5%) and the remainder
(28.5%) lived in more remote parts of the state.
Five hundred thirty were male. The mean age of the
patients studied was 37.2 years (SD 10.1 and median
36.0). On average, women were younger than men (34.6
± 9.7 vs. 39.4 ± 10.0 yrs). Table 1 shows the demographic
characteristics of the patients.
Unsafe sexual activity (defined as having unprotected sex
with partners of unknown serologic status for HIV) was
the more commonly self-reported route of HIV infection
(58.8%), followed by monogamous relationship with a
lately identified HIV-infected partner (32.8%), history of
blood-product transfusion (5.7%), and use of illicit-IV-
drugs (2.4%). Only 0.2% of the individuals denied
belonging to any of the above risk groups. Tattoos were
present in 13.5% of the sample. Risk factors differed
according to the distribution by gender: 55.8% of the
women reported an HIV-infected partner compared to
12.6% of men. Males (77.2%) reported unsafe sexual
activity more frequently than females (37.9%, p <
0.0001).
Sex-related exposure, as determined by the total number
of sexual partners through life, showed 38.1% having 1 to
5 partners, 16.5% having 6 to 10 partners, and 45.3% hav-
ing more than 10 partners.
Sexually transmitted diseases were reported by 34.2%,
with males accounting for 78.5% of the occurrences (p <
0.0001). Genital lesions were mentioned by 49.8%, and
syphilis by 21.2% of the individuals reporting STD. Ure-
thral discharge was reported by 68.1% of the men who
had STD.
A total of 716 individuals (72%) were currently undergo-
ing antiretroviral treatment and 279 (28%) reported no
treatment.
There was evidence of HBV infection in 400/1000 (40%)
subjects (anti-HBc +) and 37 (3.7%) were reactive for
Table 2: HBV markers in HIV-positive individuals in the state of Mato Grosso, Central Brazil.
Marker n (%) CI 95%
HBV exposed (Anti-HBc +ve) 400 (40.0) (36.9 – 43.1)
HBsAg +ve 37 (3.7) (2.6 – 5.2)
Previous infection 363 (36.3) (33.3 – 39.4)
Anti-HBc + Anti HBs 263 (72.4) (67.5 – 76.9)
Anti-HBc alone 100 (27.6) (23.1 – 32.5)
HBV non-exposed 600 (60.0) (56.9 – 63.0)
Anti-HBs alone 109 (18.2) (15.2 – 21.5)
* Chi-square for linear trend
Table 3: Risk factors associated with HBV infection after adjusted analysis.
Risk factors OR CI 95% P*
Male gender 1.6 1.2–2.1 0.00
Age group
17–30 1.0 - -
31–40 2.0 1.4–2.8 0.00
41–50 2.7 1.8–4.0 0.00
51–77 3.9 2.3–6.6 0.00
Sexual exposure
0 – 9 partners 1.0 - -
> 10 partners 1.4 1.1–1.9 0.01
Tattooing 1.6 1.1–2.4 0.01
IV drugs 2.3 0.9–5.7 0.07
* P-value of chi-squareBMC Infectious Diseases 2006, 6:34 http://www.biomedcentral.com/1471-2334/6/34
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HBsAg. 263 (72.4%) out of 363 patients with previous
exposure were also anti-HBs positive.
Of the remaining 600 individuals, 109 were positive for
anti-HBs alone. Testing for anti-HDV in the 37 HBsAg
positive patients was positive in only one subject (Table
2).
A multivariate analysis demonstrated that HBV exposure
was independently associated with the following factors:
male gender, older age groups, tattooing, and reporting
more than ten sexual partners throughout life (Table 3).
Reactivity for HBsAg was more common among males,
but this association was not confirmed after age adjust-
ment. After logistic regression, no association remained
positive for HBsAg carrier state.
Vaccination against hepatitis was reported by 47.6% of
subjects (defined as hepatitis B vaccine by 83.8% of those
vaccinated). HBV vaccine was indicated by the assistant
physician in 75.4% of the individuals submitted to immu-
nization. Eighty-one (27.5%) out of 291 HBV-unexposed
individuals who reported to had taken the vaccine were
anti-HBs positive. 294 (50.2%) of 585 HBV susceptible
subjects never took the vaccine.
A statistical analysis was also performed regarding vacci-
nation against HBV and seroconversion rates for anti-HBs.
A univariate analysis showed significantly higher rates of
anti-HBs in the patients with higher levels of CD4 who
reported vaccination and were without serologic evidence
of prior contact with HBV (anti-HBc negative). This asso-
ciation remained unchanged after multivariate analysis,
showing better performance of vaccinal response among
individuals with > 350 cells/mm3 (Table 4).
We have found five articles assessing prevalence of HIV-
HBV co-infection in Brazilian populations. Comparison
with the present study revealed similar anti-HBc and
HBsAg prevalence with data from the Southeast region.
Prevalence from the North and South regions were higher
than in our study (Table 5).
Discussion
High HBV infection rates have been described among
HIV-infected population worldwide [5,14,15]. The risk of
HBV-associated end-stage liver disease seems to be
increased in the setting of HIV-co-infection [3,5]. Conse-
quently, it is very important to estimate its prevalence
regionally.
In our study, we took advantage of the official policy of
the Brazilian government for the health care for HIV-pos-
itive subjects. Such policy provides, in addition to HAART
supply, measurement of HIV-RNA and CD4 cell count
every four to six months. In the present study, the survey
period lasted six months in order to include the vast
majority of patients when they returned to the Central
Laboratory for their next viral and immunological evalua-
tion. Consequently, the 1,000 individuals assessed repre-
sent almost all the HIV-positive population, diagnosed
and followed-up on in the state of Mato Grosso.
Table 4: Analysis of vaccinal response (Anti-HBs+) and CD4 level among HBV-unexposed individuals*.
CD4+ level Anti-HBs +/total (%) OR CI 95% p
0–200 6/46 (13.0) 1.0 - -
201–350 16/87 (18.3) 1.5 0.5 – 4.2 0.4
> 350 59/158 (37.3) 4.2 1.6 – 10.7 0.02
Total 81/291 (100.0)
*Adjusted for age group and gender.
Table 5: Prevalence of HBV infection in HIV-positive populations reported in different Brazilian studies.
Region (Main city) n Anti-HBc +ve HBsAg +ve IV drugs Year Reference
North (Belém) 406 51.0% (46.0–56.0) 7.9% (5.5–11.1) 10.6% (7.9–14.1) 2000 13
Central (Cuiabá) 1,000 40.0% (37.0–43.1) 3.7% (2.7–5.1) 2.4% (1.6–3.6) 2004 Present study
Southeast (Campinas) 226 44.0% (37.5–50.7) 5.3% (2.9–9.3) 29.0% (23.3–35.5) 1995 11
"  (Ribeirão Preto)  401 40.9% (36.1–45.9) 8.5% (6.0–11.8) 22.2% (18.3–26.6) 2002 10
"  (São Paulo) 1,693 38.6% (36.3–41.0) 5.7% (4.7–6.9) - 1996 12
South (Florianópolis) 93 71.2% (60.7–79.9) 24.3% (16.3–34.5) 36.5% (26.9–47.2) 1999 9BMC Infectious Diseases 2006, 6:34 http://www.biomedcentral.com/1471-2334/6/34
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The overall prevalence rate of HBV infection in the studied
population was 40.0%, higher than that found among
blood donors in Mato Grosso (approximately 10%,
according to Mato Grosso State public blood bank –
Hemomat Official Report 1999–2002). Regarding the rest
of Brazil, the present study showed similar anti-HBc prev-
alence when compared with data from the Southeast
region. Prevalence from the North and South regions were
higher than the one found in our study. Other authors
have reported prevalence of HBV markers among HIV-
positive individuals ranging from 36% to 50% (South-
east), 46.0% to 56% (North), and 60% to 79% (South),
[9-13]. The rate of HBV carriers for the present study was
also comparable to the prevalence in the Southeast and
lower than in the North and South regions. However, data
from the South region was based on a very small sample
[9]. Furthermore the very impressive presence of IVD users
in the South region suggests that a selection bias has
occurred (Table 5).
A statistical association regarding risk factors for HBV
infection showed higher prevalence in older age groups, a
well-known and widely observed fact, due to the increas-
ing risk of exposure with time. A stronger association with
the male gender was also observed, as described previ-
ously in many populational groups, probably because of
more frequent exposure to the risk factors involved in
transmission, particularly sexual contact with a greater
number of partners.
More than 10 sexual partners was another independent
risk factor for HBV infection in our study, reinforcing the
importance of this transmission route, as already
observed in the general population.
Two classic risk factors for blood-borne diseases were
associated to HBV markers: tattooing (p = 0.01) and the
use of IV drugs, although the statistical significance was
only marginal (p = 0.07) in the logistic model for the lat-
ter. This lack of significance probably occurred due to the
small number of participants reporting drug injection and
because both variables were frequently present in the
same subjects (50% of tattooed subjects were also IV drug
users). There is a striking difference between the rate of
reported intravenous drug use in the present study (2.7%)
and that of other studies conducted in the South and
Southeast regions of Brazil (22.1%, 29.0%, 36.5%) [9-
12]. The use of IV drugs was also associated to a higher
prevalence of HBV infection in these studies, reflecting the
higher transmissibility of HBV through direct blood con-
tact while sharing syringes and needles. In spite of the pos-
sibility of some participants having concealed
information about IV drug use, the difference between the
prevalence in Mato Grosso and other Brazilian regions
was quite impressive and it seems to influence the preva-
lence of HBV markers. We believe that the HIV-positive
population of Mato Grosso has a different epidemiologi-
cal profile. In fact, low-income adult women in monoga-
mous relationships composed the largest portion of the
sample. This is not the usual profile of IV drug users.
The sexual route seems to be much more implicated in
HIV spread in Mato Grosso than the parenteral route. This
finding may play a role in the lower prevalence of HBV
markers among the HIV-positive population of Mato
Grosso.
Only one (2.7%) HBsAg carrier had anti-HDV positivity.
It is considered a low HDV infection prevalence and dif-
fers from data of Brazilian surveys conducted in the gen-
eral population in the Amazonian region [16-18]. A high
HDV infection prevalence was recently shown in the por-
tion of the state of Mato Grosso that belongs to the Ama-
zonian region [18]. Nevertheless, this alarming figure was
not found among our HIV-HBV co-infected sample, since
HIV has a more urban pattern in Brazil.
Vaccination is a widely accepted strategy for lowering the
incidence of HBV infection in HIV-infected individuals
[19]. Given the increased rate of chronic hepatic disease
and more unfavorable outcome in this subpopulation,
physicians must be aware of the importance of detecting
carriers and immunizing susceptible individuals.
In our study, 47.6% of those interviewed reported vacci-
nation against hepatitis. Most (83.8%) were able to define
this as the hepatitis B vaccine. There was an impressive
number (50.2%) of HBV-unexposed individuals who had
never taken the HBV vaccine. Among the 291 individuals
without previous contact with HBV and who reported vac-
cination, only 27.5% were positive for anti-HBs. Preva-
lence of anti-HBs increased according to CD4 level, with a
well-defined trend toward higher values at the higher CD4
levels (Table 4). Although precise information regarding
the period of vaccination, the number of doses received,
and the CD4 levels during the vaccination period was fre-
quently difficult to obtain during interviews, the statistical
association suggests that CD4 levels strongly influence
vaccinal response to HBV. There are numerous reports
describing impaired response to HBV vaccine in HIV-
infected individuals [20,21]. A recently released double-
blind, randomized study evaluated several doses of vac-
cine in 210 individuals and also found lower seroconver-
sion rates among patients with CD4 <350 cells/mm3 [22].
Low seroconversion rate in the HIV-infected population is
a matter of concern, especially in patients with the lowest
CD4 levels. Alternative strategies should be developed to
improve anti-HBs production after vaccination, such as
higher dosages of the vaccine, assessment of antibody lev-BMC Infectious Diseases 2006, 6:34 http://www.biomedcentral.com/1471-2334/6/34
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els after vaccination, increasing number of doses and
revaccination after immune reconstitution. [22-24].
In conclusion, our data indicated that the HBV prevalence
in HIV-positive population in the state of Mato Grosso is
similar or slightly lower than that in other regions of Bra-
zil. A less important role of drug injection in the spread of
HIV and HBV in Mato Grosso was revealed when com-
pared to other, more developed and populous regions of
the country. However, it remains merely speculative if it
affected co-infection prevalence.
Anyway, the low HBV vaccine coverage showed by the
present survey should alert health care workers to the
need of testing for HBV markers and reinforcing HBV vac-
cination when dealing with individuals living with HIV.
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